by Jen Hodson | Nov 27, 2019 | Events, Press Releases
CULVER CITY, Calif., November 27, 2019 – NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other...
by Jen Hodson | Nov 7, 2019 | Events, Press Releases
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety Culver City, Calif., Nov. 7, 2019 – NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage...
by Jen Hodson | Aug 5, 2019 | Events, Press Releases
CULVER CITY, CALIFORNIA - August 5, 2019 NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating in the 39th Annual Canaccord Growth Conference being held in Boston from...
by Jen Hodson | Jun 24, 2019 | Press Releases
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumorsNantKwest establishes a leading portfolio of off-the shelf NK cells at clinical stage of...
by Jen Hodson | Jun 14, 2019 | Events, Press Releases
CULVER CITY, CA - June 14, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating in the 2019 Raymond James Life Sciences and MedTech Conference being held in New...
by Jen Hodson | Jun 6, 2019 | Press Releases
Culver City, CA, June 6, 2019 - NantKwest (Nasdaq:NK) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest, effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology...
